News & Updates
Filter by Specialty:
Add-on ixazomib does not improve cyclophosphamide-dexamethasone combo in frail MM patients
The addition of ixazomib to cyclophosphamide-dexamethasone treatment does not seem to result in better survival and response rates in patients with newly diagnosed and relapsed multiple myeloma (MM), a recent study has found.
Add-on ixazomib does not improve cyclophosphamide-dexamethasone combo in frail MM patients
17 May 2022Chamomile improves skin recovery in breast cancer patients with radiodermatitis
A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.
Chamomile improves skin recovery in breast cancer patients with radiodermatitis
13 May 2022Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.